Drug Approved Dogs: this caregiver-focused guide explains what drug approved dogs means in plain English, the day-to-day implications for families, and when to bring it up with a clinician. If you arrived here looking for a quick orientation on drug approved dogs, the table of contents below points to the section you need; the full guide picks up after it.
For a broader overview, see our dementia treatment and medications guide.
Table of contents
- Table of Contents
- What Is the Dog-Approved Drug Now Being Tested in Humans?
- What Did the First Human Rapamycin Trial Actually Find?
- How Loyal's LOY-001 and LOY-002 Made FDA History
- Dogs as a Bridge Species — Why This Matters for Dementia Research
- The Limitations and Risks You Should Understand
- What the IGF-1 Connection Tells Us About Human Aging
- Where This Research Heads Next
The drug is rapamycin, an immunosuppressant originally developed for human organ transplant patients that showed such striking anti-aging effects in dogs that it is now the subject of dedicated human longevity trials. In parallel, a San Francisco biotech called Loyal is developing LOY-001 and LOY-002, the first drugs in history to receive FDA recognition specifically for extending lifespan — initially in dogs, with the explicit goal of paving the way for human treatments. These are not fringe experiments. The Dog Aging Project’s rapamycin trial has enrolled over 180 dogs across multiple veterinary centers with a $7 million NIH grant backing its expansion, and the human counterpart trial has already produced its first round of results in adults aged 50 to 85.
What makes this moment unusual in medicine is the direction of translation. Normally, drugs move from lab mice to humans. Here, dogs are serving as the critical bridge species — they share more genetic similarity with humans than mice do, they develop many of the same age-related diseases including cancer, osteoarthritis, and cognitive decline, and they age on a compressed timeline that makes clinical results possible within years rather than decades. For anyone concerned about dementia, neurodegeneration, or the broader biology of aging, this pipeline from veterinary medicine to human clinical trials represents one of the most tangible research developments in recent memory. This article breaks down the science behind both rapamycin and Loyal’s drugs, what the clinical data actually shows so far, and what it means — and doesn’t mean — for people hoping these advances will eventually reach human patients.
Table of Contents
- What Is the Dog-Approved Drug Now Being Tested in Humans?
- What Did the First Human Rapamycin Trial Actually Find?
- How Loyal’s LOY-001 and LOY-002 Made FDA History
- Dogs as a Bridge Species — Why This Matters for Dementia Research
- The Limitations and Risks You Should Understand
- What the IGF-1 Connection Tells Us About Human Aging
- Where This Research Heads Next
- Conclusion
- Frequently Asked Questions
What Is the Dog-Approved Drug Now Being Tested in Humans?
Rapamycin, also known as sirolimus, is an mTOR inhibitor that was first isolated from soil bacteria on Easter Island in the 1970s. It has been used in human medicine for years — primarily to prevent organ rejection after kidney transplants and to coat cardiac stents. But researchers noticed something unexpected in animal studies: rapamycin consistently extended lifespan in mice, sometimes by as much as 25 percent. The question became whether those results would hold up in a larger, more genetically diverse animal. Dogs, it turned out, were the ideal test case. The Dog Aging Project launched TRIAD — the Test of Rapamycin in Aging Dogs — as a double-blind, placebo-controlled clinical trial across multiple veterinary centers. The study targets 580 healthy middle-aged dogs, aged seven years and older, who receive either oral rapamycin or a placebo for one year followed by two years of observation.
Early studies in dogs had already shown rapamycin could improve cardiac function and slow markers of aging, giving researchers enough confidence to commit to this larger effort. In January 2025, the project received a $7 million NIH grant to expand TRIAD, with the goal of finishing enrollment by the end of 2025 and beginning medication by spring 2026. The study is projected to conclude in November 2029. The human parallel is called PEARL — the Participatory Evaluation of Aging with Rapamycin for Longevity. This is a 48-week, double-blind, randomized, placebo-controlled trial testing intermittent low-dose rapamycin in healthy adults aged roughly 50 to 85. Participants received either 5 milligrams or 10 milligrams weekly, far lower than the doses used in transplant medicine. The distinction matters: at transplant doses, rapamycin suppresses the immune system, but at these lower doses, researchers hypothesized it might actually rejuvenate immune function and slow cellular aging without the serious side effects.
What Did the First Human Rapamycin Trial Actually Find?
The PEARL trial results were encouraging but far from definitive. Low-dose rapamycin was well tolerated over the full year of the study, with no increase in serious adverse events compared to placebo. that alone was significant — one of the primary concerns about repurposing an immunosuppressant for healthy people was whether it would leave them vulnerable to infections or other complications. At the doses tested, it did not. The trial also produced several intriguing biological signals. Women in the rapamycin group showed improved muscle mass, while men showed improved bone mass. Both outcomes matter enormously for aging: sarcopenia and osteoporosis are major contributors to falls, fractures, disability, and the kind of physical decline that accelerates cognitive deterioration.
Perhaps most notably, rapamycin reduced senescent cells — sometimes called “zombie cells” — which accumulate with age and drive chronic inflammation linked to Alzheimer’s disease, cardiovascular disease, and other conditions. However, researchers were careful to describe the evidence as preliminary. These are biomarker improvements in a relatively small trial, not proof that rapamycin extends human lifespan or prevents dementia. A 2025 review published in Frontiers in Aging put it bluntly: there is “no clear clinical evidence” yet that rapamycin’s animal longevity benefits translate to humans. The authors called for larger, better-designed human trials before anyone should consider rapamycin a proven anti-aging intervention. This is a critical caveat for anyone tempted to seek out rapamycin through off-label prescriptions, which some longevity enthusiasts have already been doing. The drug has real side effects at higher doses, including impaired wound healing, elevated cholesterol, and mouth sores. Without knowing the right dose, duration, and patient profile for longevity use, self-prescribing carries genuine risk.
How Loyal’s LOY-001 and LOY-002 Made FDA History
While rapamycin is a repurposed human drug being tested in dogs, Loyal took the opposite approach: building drugs from the ground up to extend canine lifespan, with the long-term vision of translating that work to humans. The company, founded in San Francisco, developed two compounds targeting IGF-1, or insulin-like growth factor-1. this hormone is central to growth and metabolism, and elevated levels have been linked to accelerated aging and shorter lifespans across multiple species. Large-breed dogs, which produce more IGF-1, live significantly shorter lives than small breeds — a Great Dane might live seven years while a Chihuahua reaches sixteen. LOY-001, designed for large-breed dogs, works by reducing IGF-1 levels. In November 2023, the FDA agreed that Loyal’s data supported a “Reasonable Expectation of Effectiveness” — an RXE determination that had never before been granted for any lifespan extension drug in any species. That decision was historic, not just for veterinary medicine but for the entire field of longevity research.
It established that a regulatory body could evaluate and recognize evidence for a drug intended to make animals live longer. Loyal expects LOY-001 to reach the market in 2026 pending conditional FDA approval. LOY-002, designed for senior dogs aged seven and older, functions as a caloric restriction mimetic — it produces some of the biological effects of eating less without actually requiring the animal to eat less, again by targeting IGF-1. It received its own RXE acceptance from the FDA in February 2025 and then cleared a second major regulatory hurdle when the FDA accepted its safety package in December 2025. That completed two of the three requirements for conditional approval. Its pivotal efficacy trial, called the STAY study, enrolled 1,300 dogs across 70 veterinary clinics, making it the largest clinical trial in veterinary medicine history. Enrollment was completed in July 2025.
Dogs as a Bridge Species — Why This Matters for Dementia Research
The reason this veterinary research has direct relevance to human brain health is not just scientific optimism. Dogs develop a condition strikingly similar to Alzheimer’s disease. As they age, many dogs accumulate beta-amyloid plaques in their brains, experience cognitive dysfunction syndrome — characterized by disorientation, disrupted sleep cycles, loss of housetraining, and reduced social interaction — and show patterns of neurodegeneration that mirror what happens in human dementia patients. Unlike laboratory mice, which must be genetically engineered to develop Alzheimer’s-like pathology, dogs develop it naturally. This makes dogs a uniquely valuable model for testing whether interventions that slow biological aging also protect the brain. If rapamycin reduces senescent cells and improves physical function in dogs, does it also delay or prevent cognitive decline? The TRIAD study, with its two-year observation period after treatment, should provide data on cognitive outcomes alongside cardiac and physical health markers. Similarly, if reducing IGF-1 through Loyal’s drugs extends overall canine lifespan, researchers will be watching closely for whether those extra years come with preserved cognitive function or simply a longer period of decline.
The tradeoff to acknowledge is time. TRIAD won’t conclude until November 2029. The STAY study results for LOY-002 are still being analyzed. And even with positive results, translating dog findings to human treatments takes additional years of clinical development. Loyal has stated that its canine work is intended to lay groundwork for future human longevity treatments, but no human trials of LOY-001 or LOY-002 have been announced yet. For families dealing with dementia now, these are promising but distant developments. They are not a reason to delay evidence-based interventions that exist today.
The Limitations and Risks You Should Understand
The biggest limitation of this entire field is the gap between biomarkers and outcomes. The PEARL trial showed rapamycin reduced senescent cells and improved muscle and bone mass. But those are surrogate endpoints — measurable changes that correlate with better health outcomes without directly proving that people who take rapamycin will live longer, stay sharper, or avoid dementia. Proving actual lifespan extension in humans would require a trial lasting decades, which is precisely why dogs, with their compressed lifespans, are so valuable as an intermediate step. There is also the issue of extrapolation. Rapamycin has extended lifespan in yeast, worms, flies, and mice, but each species responded differently, and the optimal dosing varied enormously. A 2025 review noted that what works in a mouse may not work in a dog, and what works in a dog may not work in a human.
The biology of mTOR signaling is complex, with different effects on different tissues, and chronic suppression of mTOR can impair immune function, glucose metabolism, and wound healing. Intermittent dosing, as used in PEARL, may avoid these problems, but that hypothesis needs much more testing. For Loyal’s drugs, the limitation is regulatory and commercial rather than purely scientific. Even if LOY-001 reaches the market in 2026, it will be approved only for dogs. The leap from a veterinary product targeting IGF-1 to a human pharmaceutical is enormous — requiring separate human pharmacology studies, toxicology packages, and clinical trials that could take a decade or more. The scientific rationale is compelling: certain human centenarians have been shown to carry genetic variants that produce lower IGF-1 levels. But having a biological rationale and having an approved human drug are very different things.
What the IGF-1 Connection Tells Us About Human Aging
The link between IGF-1 and longevity is one of the most consistent findings in aging biology. Across species from worms to humans, lower IGF-1 signaling is associated with longer life. In humans, studies of centenarians — particularly Ashkenazi Jewish populations studied by researchers at Albert Einstein College of Medicine — have identified genetic variants in the IGF-1 receptor that reduce its activity and appear to be enriched in people who live past 100.
Loyal’s entire drug platform is built on pharmacologically mimicking what these centenarians achieve genetically. The practical implication is that if Loyal’s drugs succeed in extending healthy lifespan in dogs by modulating IGF-1, they will have validated a druggable pathway that already has human genetic evidence behind it. That does not guarantee a human drug will follow, but it substantially de-risks the hypothesis and gives future human trials a much clearer target than the broad, undefined goal of “slowing aging.”.
Where This Research Heads Next
The next three to four years will be decisive. TRIAD’s completion in November 2029 will provide the first large-scale, rigorously controlled evidence for whether rapamycin extends healthy lifespan in dogs. Loyal’s STAY study results, once analyzed, will determine whether LOY-002 earns its third and final regulatory clearance for conditional approval. And the PEARL trial’s findings, while preliminary, have already generated enough interest that larger human rapamycin trials are being planned.
For the dementia and brain health community specifically, the most important data point to watch is whether these interventions protect cognition — not just extend life. A drug that adds years of severe cognitive decline would be a pyrrhic victory. The hope, grounded in the biology of mTOR and IGF-1 signaling, is that slowing the fundamental processes of aging will delay all age-related diseases simultaneously, including neurodegeneration. If the dog studies bear that out, the case for accelerating human trials will be difficult to ignore.
Conclusion
Rapamycin and Loyal’s LOY-001 and LOY-002 represent two distinct but converging approaches to one of medicine’s oldest questions: whether aging itself can be treated. Rapamycin, already a human drug being tested in dogs and now back in human longevity trials, has shown early promise in reducing cellular markers of aging in people aged 50 to 85. Loyal’s drugs, engineered specifically for canine lifespan extension, have achieved FDA recognitions that were previously thought impossible and are on track for market availability as early as 2026. Both approaches are generating data in dogs that would take decades to produce in human studies alone.
None of this is ready for clinical use in humans as an anti-aging therapy. The evidence is preliminary, the trials are ongoing, and the gap between promising biomarkers and proven health outcomes remains wide. But for anyone following dementia research and brain health, the pipeline from these dog studies to human applications is worth watching closely. The biology of aging does not respect species boundaries as neatly as we once assumed, and what these dogs teach us may ultimately reshape how we approach neurodegeneration, cognitive decline, and the long search for ways to keep the human brain healthy across a full lifespan.
Frequently Asked Questions
Is rapamycin available as an anti-aging drug for humans right now?
No. Rapamycin is FDA-approved for preventing organ transplant rejection and certain cancers, but it is not approved for longevity or anti-aging use. Some doctors prescribe it off-label, but this carries risks including impaired immune function, elevated cholesterol, and mouth sores. The PEARL trial showed promising preliminary results, but researchers have emphasized that larger trials are needed before rapamycin can be recommended for healthy aging.
Can I get Loyal’s lifespan extension drugs for my dog today?
Not yet. LOY-001 is expected to reach the market in 2026, pending conditional FDA approval. LOY-002 has cleared two of three major regulatory hurdles but still requires completion of its efficacy review. Neither drug is currently available for purchase or prescription.
Do these dog longevity drugs have anything to do with dementia treatment?
Not directly, but the underlying biology is relevant. Dogs naturally develop cognitive dysfunction syndrome, which resembles Alzheimer’s disease. If rapamycin or IGF-1-lowering drugs slow biological aging in dogs and preserve their cognitive function, that strengthens the scientific case for testing similar approaches in human neurodegeneration. However, no dementia-specific claims have been made for any of these drugs.
How is the TRIAD dog study different from Loyal’s STAY study?
TRIAD tests rapamycin, an existing human immunosuppressant, in 580 healthy middle-aged dogs to see if it slows aging. It is run by the Dog Aging Project with NIH funding. The STAY study tests LOY-002, a purpose-built lifespan extension drug, in 1,300 senior dogs across 70 veterinary clinics. STAY is run by Loyal, a private biotech company. They target different biological pathways — mTOR for rapamycin, IGF-1 for LOY-002.
What were the actual results of the human rapamycin trial?
The PEARL trial found that low-dose rapamycin taken weekly for 48 weeks was well tolerated with no increase in serious adverse events compared to placebo. It improved muscle mass in women, bone mass in men, and reduced senescent cells associated with age-related disease. However, these are preliminary findings from a small study, and a 2025 review in Frontiers in Aging concluded there is still no clear clinical evidence that rapamycin extends human lifespan.
Will Loyal’s dog drugs ever be available for humans?
Loyal has stated that its canine work is intended to lay groundwork for future human longevity treatments, and the biological rationale is strong — certain human centenarians naturally have lower IGF-1 levels. However, no human trials of LOY-001 or LOY-002 have been announced. Any human application would require years of additional development, separate clinical trials, and regulatory approval.
You Might Also Like
- This Drug Approved for One Condition Treats 12 Others Off-Label
- The Medication Approved by FDA That Is Still Being Studied for Safety
- The Drug Doctors Use When Anesthesia Doesn’t Fully Wear Off
Sources used for this Drug Approved Dogs guide
- National Institute on Aging — Alzheimer’s treatments
- FDA — Approved Drugs for Alzheimer’s
- Alzheimer’s Association — Medications for Memory
This article is informational and not medical advice. See our Editorial Policy for how we research and review content. Last reviewed May 30, 2026.
